Inhibitory Behavior of AG-120
In vitro, AG-120 showed no time-dependence in IC50 values between 1 and 16 hours of incubation for the mIDH1-R132 homodimer. AG-120 showed non-competitive inhibitory behavior with respect to the α-KG substrate ( Figure S1 ) and appears to be non-competitive with respect to the NADPH cofactor by standard equilibrium kinetic analysis ( Figure S2 ).
These observations are consistent with AG-120 being a rapid equilibrium inhibitor of the mIDH1-R132H homodimer in the presence or absence of substrate and cofactor. However, we cannot confirm this mode of action because NADPH is found to be tightly pre-bound in recombinant enzyme preparations. 1 Against the IDH1-WT homodimer, AG-120 showed uncompetitive inhibition with respect to the NADP cofactor ( Figure S3 ). In the presence of increasing concentrations of AG-120, the observed rate constant (kobs) was a hyperbolic function of inhibitor concentration. Along with the observed time-dependence in IC50 values between 1 and 16 hours, these data are consistent with AG-120 being a slow-binding inhibitor of the IDH1-WT homodimer ( Figure S4 ).
With respect to the inhibition of the IDH1-WT enzyme, it is worth noting that mice with complete knock-out of Idh1 showed completely normal development and fertility, although they were more susceptible to lethal doses of lipopolysaccharide than WT litter-mates, 2 suggesting that inhibition of IDH1 under homeostasis should be tolerable. Overall, preclinical profiling of AG-120 fully supports further clinical studies in the context of diseases associated with mutation of IDH1. Tables   Table S1 . In vitro ADME and in vivo PK properties of AGI-14100
Supplementary Figures and
In vitro ADME In vivo PK CLp (L/hr/kg), from 1 mg/kg IV dose Rat/Dog/Cynomolgus 0.45/0.12/0.22 t½ (hr) Rat/Dog/Cynomolgus 9.9/32.5/12.5 F (%), from 10 mg/kg PO dose Rat/Dog/Cynomolgus 44/18/43 ADME, absorption, distribution, metabolism, and excretion; CLp, clearance; CYP, cytochrome P450; Eh, microsome stability recorded as hepatic extraction ratio in liver microsomes; F, oral bioavailability; hPXR, human pregnane X receptor; IV, intravenous; PK, pharmacokinetic; PO, oral; t½, half-life. . AG-120 showed non-competitive inhibition with respect to alpha-ketoglutarate (α- Linear regression of the reciprocal plots for each titration series of varying substrate versus varied fixed concentration of inhibitor intersects at a negative value on the x-axis, indicative of a non-competitive mode of inhibition. AG-120 is a non-competitive inhibitor of the mIDH1-R132H homodimer with respect to NADPH. Linear regression of the reciprocal plots for each titration series of varying cofactor versus fixed concentration of inhibitor intersects at a negative value on the x-axis, indicative of a non-competitive mode of inhibition. However, it is not conclusive that AG-120 can bind to the apo-form of the enzyme given that recombinantly expressed mIDH1-R132 enzymes exhibit low nM Km values for NADPH and already contain pre-bound co-factor (observed in crystallography studies, data not shown). In the presence of increasing concentrations of AG-120, the observed rate constant (kobs) is a hyperbolic function of inhibitor concentration, indicative of AG-120 being a slow-binding inhibitor of the IDH1-WT homodimer. classification. Description of the karyotypes followed the International System for Human Cytogenetic Nomenclature. Enhanced ability of progenitor cells to form differentiated colonies, consistent with the onset of cellular differentiation, was observed for mIDH1, but not IDH1-WT, patient myeloblasts when grown for 12 days in methylcellulose in the presence of AG-120 (5 μM) compared with vehicle control (DMSO, Figure S5A ). Maturation of AML blasts was also evaluated by flow cytometry analysis for changes in cell-surface markers associated with myeloid differentiation (CD15, CD24, CD11b, and CD14). Treatment of mIDH1 AML cells with AG-120 always induced increases in one or more of these differentiation markers, although there was significant heterogeneity in the marker(s) induced, as well as in the kinetics of their appearance, with both features varying from one patient sample to another. This is illustrated
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Figure S2. AG-120 showed non-competitive inhibition with respect to the NADPH cofactor
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in Figure S5B , which shows that treatment of mIDH1 blasts (from Patients #2 and #4) in compared with DMSO control ( Figure S5C ). These data show that AG-120 induces myeloid differentiation in mIDH1-R132H and -R132C, but not IDH1-WT, primary human AML BM samples.
Scheme S1. Synthesis of AG-120
Starting from the commercially available 3,3-difluorocyclobutan- 
Biochemistry and Cell Biology Assay Methods
Expression and purification of WT and mutant IDH enzymes
WT and mutant IDH1 and IDH2 enzymes were expressed and purified as previously reported. Florescence was read on a Spectramax plate reader at Ex 544 Em 590. Recombinant protein was expressed and purified as previously described. 5 Compounds or compound dilutions were prepared in 100% dimethyl sulfoxide (DMSO) concentration and diluted 1:100 into the final reaction. mIDH1-R132C was assayed under similar conditions, with the exception that the 1X Buffer was 50 mM K2HPO4 pH 6.5, 40 mM NaHCO3, 5 mM MgCl2, 10% glycerol, 0.03% w/v BSA.
Assay of the IDH1-WT enzyme reaction for determination of inhibitor potency
IDH1-WT enzyme was assayed in a modified version of the assay used for mIDH1-R132H.
Since this enzyme converts NADP to NADPH stoichiometrically with the conversion of isocitrate to α-KG, NADPH product can be continuously assayed by direct coupling to the diaphorase/resazurin system and reading resorufin production at Ex 544 Em 590. Assays were conducted in 50 L of 1X Buffer (150 mM NaCl, 20 mM Tris pH 7.5, 10 mM MgCl2, 0.05% (w/v) BSA, 2 mM beta-mercaptoethanol [B-ME]) containing 50 M NADP, 70 M DL-isocitrate, and 31.2 ng/mL IDH1-WT enzyme (reaction time 1 or 16 hours). The direct coupling system comprised 20 g/mL diaphorase and 40 M resazurin.
Assay of the IDH2-WT enzyme reaction for determination of inhibitor potency
Inhibitory potency of compounds against the IDH2-WT enzyme was determined in a coupled assay to diaphorase. In this assay, production of NADPH by IDH2-WT was linked to a concomitant reduction of resazurin to the highly fluorescent resorufin. Enzyme was diluted to 0.06 g/mL in 40 L 1X Assay Buffer (150 mM NaCl, 50 mM potassium phosphate pH 7, 10 mM MgCl2, 10% glycerol, 2 mM B-ME, 0.03% BSA), to which 1 L of compound was added in DMSO. The mixture was incubated for 16 hours at room temperature (RT). The reaction was started with the addition of 10 L of Substrate Mix (200 M isocitrate, 175 M NADP, 60 g/mL diaphorase, 200 M resazurin, in 1X Assay Buffer), and run for 30 minutes at RT. The reaction was halted with the addition of 25 L of 6% sodium dodecyl sulfate and read on a Spectramax Plate Reader at Ex544/Em590.
Assay of the mIDH2-R140Q and mIDH2-R172K enzyme reaction for determination of inhibitor potency
Inhibitory potency against the mIDH2-R140Q and mIDH2-R172K enzymes was determined in an endpoint assay in which the amount of NADPH remaining at the end of the reaction was measured by the addition of a large excess of diaphorase and resazurin. mIDH2-R140Q was diluted to 0.25 g/mL in 40 L 1X Assay Buffer (150 mM NaCl, 50 mM potassium phosphate pH 7.5, 10 mM MgCl2, 10% glycerol, 2 mM B-ME, 0.03% BSA) and incubated for 16 hours at 25°C in the presence of 1 L of compound in DMSO. The reaction was started with the addition of 10 L of Substrate Mix (20 M NADPH, 8 M α-KG, in 1X
Assay Buffer) and incubated for 1 hour at 25°C. Then, remaining NADPH was measured by the addition of 25 L of Detection Mix (36 g/mL diaphorase, 18 M resazurin in 1X Assay Buffer), incubated for 5 minutes at 25°C, and read as described above. mIDH2-R172K was assayed as for mIDH2-R140Q with the following modifications: 1.25 g/mL of protein was used, the Substrate Mix contained 50 M NADPH and 6.4 M α-KG, and the compound was incubated for 1 hour before starting the reaction.
Cell lines
Human glioblastoma astrocytoma (U87MG) pLVX-IDH1-R132H was generated in-house using U87MG (ATCC, #HTB-14) cells and pLVX-IRESNeo. High titers of recombinant, replication-incompetent virions were generated using a Lenti-X HTX Packing system 
Cell assays
Cells were seeded in their respective growth media at a density of 5000 (U87MG, HCCC-9810, COR-L 105) or 2500 (HT1080) cells/well into 96-well microtiter plates and incubated overnight at 37°C and 5% CO2. The next day, AG-120 was prepared in 100% DMSO as a 10 mM stock and then diluted in media for a final concentration of 0.1% DMSO. Highest concentration dose was 3 µM. Medium was removed from the cell plates and 200 µL of the compound dilutions were added to each well. For neurospheres, compounds and cells (40,000/well) were plated together at the same time. After 48 hours of incubation with compound at 37°C, 100 µL of media was removed from each well and analyzed as described below. The cell plates were then allowed to incubate another 24 hours. At 72 hours post compound addition, a 10 mL/plate of Promega Cell Titer Glo reagent was thawed and mixed.
The cell plate was removed from the incubator and allowed to equilibrate to RT. Then 100 µL of reagent was added to each well of media. The cell plate was placed on an orbital shaker for 10 minutes and then allowed to sit at RT for 20 minutes. The plate was then read for luminescence with an integration time of 500 ms to determine any compound effects on growth inhibition (half maximal inhibition of cell proliferation, GI50).
Cellular half-maximal inhibitory concentration (IC50), 90% maximal IC (IC90), percent maximum 2-HG inhibition, and growth inhibition were calculated as described below.
The concentrations of 2-HG in media were determined using a non-validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.
The following protein precipitation method was used for sample preparation:
 A 30 μL aliquot of 80:20 methanol (MeOH):H2O extract was mixed with 170 μL of acetonitrile (MeCN) with internal standard ( 13 C5-2-HG, 0.2 μg/mL).
 Samples were vortexed for 5 minutes to mix well and centrifuged at 400 rpm for 10 minutes.
 100 μL of supernatant was transferred and diluted with 100 μL of H2O and mixed well.
 40 μL was injected onto the LC-MS/MS for analysis.
The instrument setup consisted of a Thermo TSQ Vantage mass spectrometer equipped with Accela high-performance liquid chromatography (HPLC) pumps. An isocratic gradient method was used at a flow rate of 1 mL/min. The HPLC column used was Bio-Rad, Aminex value >0.98 in linear regression. The peak area ratios of the analyte relative to the internal standard were used for 2-HG quantitation. Linearity was achieved in the 2-HG concentration range from 10 to 30,000 ng/mL for cell pellets.
Generation of HT1080 mIDH1-R132C xenografts
All animal studies were approved by the Institutional Animal Care and Use Committee and conducted in compliance with all national and local guidelines and regulations. 
IDH mutational status
Genomic DNA was purified from diagnostic PB and/or BM specimens using the Qiagen DNeasy extraction kit following the manufacturer's instructions. IDH1/2 mutational status was analyzed by PCR amplification of IDH genes (exon 4 genomic regions, containing the mutational hotspot codon mIDH1-R132 and codons mIDH2-R140 and -R172) and direct sequencing, as reported. 
General Synthetic Procedures and Experimental Notes
In the following examples, the chemical reagents were purchased from commercial sources 
General procedure for the Ugi reaction 8-15
A mixture of aldehyde (3.5 mmol) and aniline (3.5 mmol) in MeOH (8 mL) was stirred at RT for 30 minutes. Then, acid (3.5 mmol) was added and the reaction mixture was stirred for another 30 minutes. Isocyanide (3.5 mmol) was then added. The resulting mixture was then stirred at RT overnight and quenched by addition of H2O. The resulting mixture was partitioned between ethyl acetate (EtOAc) and H2O. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4, and then concentrated. The residue was purified by silica gel column chromatography using dichloromethane (DCM)/MeOH as eluent to afford the desired product. [16] [17] [18] [19] A mixture of amine (0.30 mmol), aryl bromide (0.30 mmol), Cs2CO3 (129 mg, 0.39 mmol), Pd2(dba)3 (18 mg, 0.02 mmol), and Xantphos (9.4 mg, 0.02 mmol) in 1,4-dioxane (10 mL) was stirred under nitrogen atmosphere at 80°C overnight. After filtration, the filtrate was concentrated in high vacuo and the residue was purified by prep-TLC to give the desired products.
General procedure for the Buchwald reaction
Synthetic Details and Characterization of Compounds
Compound 2 was prepared according to the following scheme, using the following protocol:
Step A: N-(3,3-difluorocyclobutyl)formamide (13). A 2-L sealed reactor was charged with 3,3-difluorocyclobutanamine hydrochloride (12) (87 g, 0.61 mol), trimethylamine (TEA; 170 mL, 1.22 mol), ethyl formate (HCOOEt; 850 mL, 10.57 mol). The mixture was heated at 85°C overnight. The reaction mixture was cooled and filtered. The cake was washed with EtOAc (3 × 200 mL), and the combined filtrate was concentrated under reduced pressure.
The residual solid was dissolved in EtOAc (600 mL) and filtered. The filtrate was concentrated under reduced pressure. The residue was triturated with n-hexane (400 mL) and filtered. The solid was collected and dried to afford 74 g desired product (13) as off-white solid (86% yield).
Step B: 1,1-Difluoro-3-isocyanocyclobutane (14) . To a solution of N-(3,3-difluorocyclobutyl)formamide (13) (37 g, 0.274 mol) and triphenylphosphine (PPh3; 79.1 g, 0.301 mol) in DCM (500 mL) were added CCl4 (42.1 g, 0.274 mol) and TEA (27.73 g, 0.274 mol). The reaction mixture was stirred overnight at 45°C under the atmosphere of N2.
The resulting mixture was evaporated in vacuo at 0°C. The residue was suspended in diethyl ether (Et2O) (50 mL) at 0°C for 30 minutes and filtered. The precipitate was filtered and the filtrate was evaporated to ~50 mL at 0°C under reduced pressure. The residue was purified by column chromatography eluting with Et2O to afford the desired product 14 as light brown oil (36 g [67% purity, based on 1 H NMR], 75% crude yield).
Step C: Tert-butyl 2-((1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)(3-fluorophenyl)amino)-2-oxoethylcarbamate (20).
A mixture of 2-chlorobenzaldehyde (0.31 mL, 2.74 mmol) and 3-fluoroaniline (0.26 mL, 2.74 mmol) in dry MeOH (2 mL) was stirred at RT for 0.5 hour, followed by addition of 2-(tert-butoxycarbonylamino)acetic acid (479 mg, 2.74 mmol). The resulting mixture was stirred at RT for 10 minutes followed by addition of 3,3-difluoroisocyanobutane (67% purity, 500 mg, 4.27 mmol). Step
D: 2-Amino-N-(1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-N-(3-fluorophenyl) acetamide hydrochloride (21). A mixture of tert-butyl 2-((1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)(3-fluorophenyl)amino)-2-oxoethylcarbamate
(500 mg) in 4N HCl in EtOAc (20 mL) was stirred at RT overnight. The mixture was filtered to give the desired product (quant. yield). MS: 426.2 (M+1) + .
Step E: Compound 2 To a solution of 2-amino-N-(1-(2-chlorophenyl)-2-(3,3-difluoro cyclobutylamino)-2-oxoethyl)-N-(3-fluorophenyl) acetamide hydrochloride 21 (100 mg) in saturated aqueous NaHCO3 (10 mL) and tetrahydrofuran (THF) (10 mL) was added methyl carbonochloridate (1 mL). The mixture was stirred at RT overnight. Saturated aqueous NaHCO3 was added to the mixture until pH reached 9 and the mixture then extracted by EtOAc. Combined organic layers were dried, filtered, and concentrated. The residue was purified by flash chromatography using DCM/MeOH (V:V, 20:1) as eluent to give the desired product (66.5 mg, 60% yield Compound 3 was prepared according to the following scheme, using the following protocol:
Step A: (S)-1-(methoxycarbonyl)pyrrolidine-2-carboxylic acid. Methyl carbonochloridate (1.65 g, 17.4 mmol) was added to a solution of (S)-pyrrolidine-2-carboxylic acid (22) (1 g, 8.7 mmol) in a solution of THF (10 mL) and saturated NaHCO3 (10 mL) at 0°C and stirred at RT overnight. The mixture was extracted with EtOAc and the organic layer was concentrated to afford the desired product 23 (1.2 g, 80% yield) as colorless oil.
Step B: Compound 3. 
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Compound 4 was prepared according to the following scheme, using the following protocol:
Step A: (S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)pyrrolidine-2-carboxylic acid (24). (S)-pyrrolidine-2-carboxylic acid 22 (1 g, 8.7 mmol) was dissolved in 1,4-dioxane (4 mL) and H2O (15 mL), and cooled to 0°C. K2CO3 (3.24 g, 23 mmol) was added, and then (9H-fluoren-9-yl)methyl chloroformate (2.3 g, 8.3 mmol) was added in portions. The mixture was stirred at RT overnight and H2O (10 mL) was added. The mixture was extracted with Et2O (2 × 20 mL).The aqueous phase was acidified with aqueous HCl (1 M) to pH 2-3, and extracted with DCM (3 × 50 mL). Combined organic layers were dried over Na2SO4, filtered, concentrated to dryness to give the desired product 24 as a white solid (2.8 g, 95% yield).
MS: 338 (M+1) + .
Step 
Step C: (S)-N-((S)-1-(2-chlorophenyl)-2-(3,3-difluorocyclobutylamino)-2-oxoethyl)-N-(3-fluorophenyl)pyrrolidine-2-carboxamide (26). (S)-(9H
carbamoyl)pyrrolidine-1-carboxylate 25 (370 mg, 0.53 mmol) was dissolved in CH3CN (5 mL). Piperidine (1 mL) was added dropwise. The mixture was stirred at 40°C overnight, then H2O (10 mL) was added. The resulting mixture was extracted with EtOAc (3 × 50 mL).
Combined organic layers were dried over MgSO4, filtered, concentrated to dryness to give crude product 26 (145 mg, 57% yield). MS: 466 (M+1) + .
Step 1H), 1H), 4H), 6.43 (s, 1H), 6.12 (s, 1H), 4.92 (d, J = 6.8 Hz, 1H), 1H), 3H) Compound 9 was prepared according to the following scheme, using the following protocol:
Step with aqueous LiCl (10%) and brine, dried over anhydrous Na2SO4, and then concentrated.
The residue was purified by column chromatography (silica gel, 0-25% DCM in petroleum ether) to afford the desired product 28 (6.7 g, 91.5% yield) as colorless oil. MS: 360.2 (M+1) + .
Step B: (2S,4S)-1-tert-butyl 2-methyl 4-((tert-butyldimethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate (29). To a solution of sodium periodate (NaIO4; 7.5 g, 35.0 mmol) in H2O (80 mL) was added ruthenium oxide (RuO2; 370 mg, 2.8 mmol) under nitrogen. The resulting green-yellow solution was stirred for 5 minutes followed by addition of (2S,4S)-1-tert-butyl-2-methyl4-((tert-butyldimethylsilyl)oxy)pyrrolidine-1,2-dicarboxylate 28 (5.0 g, 14.0 mmol) in EtOAc (44 mL) in one portion. The mixture was stirred at RT overnight. The resulting mixture was then diluted with EtOAc and filtered through a pad of Celite. The organic layer was separated and washed with saturated aqueous NaHSO3, which resulted in precipitation of Ru black. The organic layer was then washed with brine and dried over anhydrous Na2SO4.
Evaporation of the solvent gave the desired product 29 (4.8 g, 92 .3% yield) as colorless oil.
MS: 374.2 (M+1) + .
Step C: (2S,4S)-4-((tert-butyldimethylsilyl)oxy)-5-oxopyrrolidine-2-carboxylic acid (14) .
TFA (6 mL) was added to a solution of (2S,4S)-1-tert-butyl 2-methyl 4-((tertbutyldimethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate 29 (2.5 g, 6.68 mmol) Step D: The same as general procedure for Ugi reaction set forth above.
Step E: The same as general procedure for Buchwald reaction set forth above.
Compound 11 was prepared according to the following scheme:
Step A: Benzyl(3-fluoro-5-nitrophenyl)sulfane (35). To a solution of 1, 3-difluoro-5-nitrobenzene 34 (15.9 g, 100 mmol) in DMF (160 mL) was added K2CO3 (15.8 g, 110 mmol) 26 and phenylmethanethiol (Ph-SH; 12.4 g, 100 mmol) at 0C. The mixture was stirred at RT for 2 hours. The resulting mixture was concentrated in high vacuo to afford the crude product 35 as yellow oil, which was used for the next step without further purification.
Step B: 3-Fluoro-5-nitrobenzene-1-sulfonyl chloride (36). Benzyl(3-fluoro-5-nitrophenyl)sulfane 35 (3.0 g) was dissolved in DCM (30 mL). To this solution, deionized H2O (30 mL) was added. Then chlorine was bubbled slowly into the stirred reaction mixture until the complete consumption of the starting material as monitored by TLC. The organic layer was separated, washed with saturated aqueous Na2S2O3 solution, dried and concentrated to afford the crude product 36, which was used for the next step without further purification.
Step C: N-tert-butyl-3-fluoro-5-nitrobenzenesulfonamide (37). 3-Fluoro-5-nitrobenzene-1-sulfonyl chloride 36 was dissolved in dry dioxane (30 mL). The solution was cooled to 0C, and tert-butylamine (NH2tBu; 10 mL) was slowly added, after which the mixture was warmed to RT and stirred for 2 hours. The mixture was concentrated and the residue was purified by column chromatography (silica gel, MeOH/DCM = 0:100 to 10:90) to afford the desired product 37 (2.2 g, 70% yield Step D: 3-Amino-N-tert-butyl-5-fluorobenzenesulfonamide (38). N-tert-butyl-3-fluoro-5- nitrobenzenesulfonamide 37 (1.0 g, 3.6 mmol), iron powder (1.0 g, 18 mmol) and NH4Cl
(1.0 g, 18 mmol) were mixed in EtOH (95%, 10 mL). The mixture was refluxed for 16 hours then filtered. The filtrate was concentrated and the residue was purified by column chromatography to afford the desired product 38 (0.62 g, 70% yield). 1 H NMR (400 MHz, DMSO-d6): δ 7.45 (s, 1H), 6.88-6.85 (m, 1H), 6.66-6.62 (m, 1H), 6.48-6.42 (m, 1H), 5.89 (s, 2H), 1.11 (s, 9H) .
Step E: The same as general procedures for Ugi reaction set forth above.
Step F: The same as general procedures for Buchwald reaction set forth above.
Step Compound AG-120 was prepared according to the following scheme, using the following protocol:
Step Step B: Compound AG-120. Pd2(dba)3 (17 g, 18.6 mmol) was added to a solution of 2-(2- and stirred at 100C for 3 hours. The mixture was filtered and the filtrate was concentrated, then the diastereomeric residue was separated by column chromatography on silica gel and eluted with DCM/EtOAc (100:1 to 4:1) to give the desired isomer, which was then further purified by crystallization from EtOAc to get the desired product AG-120 (95 g, 22% yield, 
